Session » Muscle Biology, Myositis & Myopathies Poster I

Date: Sunday, November 10, 2019

Time: 9:00AM-11:00AM

Meeting: 2019 ACR/ARP Annual Meeting

9:00AM-11:00AM: Abstract Number: 389

ACR/EULAR Criteria for Myositis and Systemic Sclerosis Lack Sensitivity for Scleromyositis

9:00AM-11:00AM: Abstract Number: 405

Anti-MDA5 Dermatomyositis: A Case Series, Systematic Review and Meta-analysis of the Literature

9:00AM-11:00AM: Abstract Number: 409

Antisynthetase Syndromes: Correlation of Indirect Immunofluorescence Patterns with Diagnosis Criteria Fulfillment

9:00AM-11:00AM: Abstract Number: 404

Autoantibody Profiles Delineate Three Distinct Subsets of Scleromyositis

9:00AM-11:00AM: Abstract Number: 402

Chronic Disease Course and IVIg-dependance in Long-term Follow-up of Anti-HMGCR Immune-mediated Necrotizing Myopathy

9:00AM-11:00AM: Abstract Number: 397

Clinical Features of Polymyositis and Dermatomyositis Patients with Severe Dysphagia

9:00AM-11:00AM: Abstract Number: 396

Clinical Manifestations and Comparison of Subtypes of Juvenile Idiopathic Inflamatory Myopathies: Data from the REMICAM Registry

9:00AM-11:00AM: Abstract Number: 412

Elevated Serum BAFF Levels in Patients with Dermatomyositis: Association with Interstitial Lung Disease

9:00AM-11:00AM: Abstract Number: 411

Frequency and Staining Patterns of Antinuclear Antibodies in Myositis Patients Without Known Myositis-specific Autoantibodies

9:00AM-11:00AM: Abstract Number: 408

Frequency of Concomitant Non-aminoacyl-transfer-RNA Synthetase Autoantibodies in Patients with Antisynthetase Syndrome

9:00AM-11:00AM: Abstract Number: 392

Management of Idiopathic Inflammatory Myopathies Using Intravenous Immunoglobulin Therapy: A Retrospective Cohort Study

9:00AM-11:00AM: Abstract Number: 406

Myositis Related Antibodies and Interstitial Lung Disease: Variables Associated with Baseline Lung Function and Functional Improvement: Results from a Multicentric Latin-american Cohort

9:00AM-11:00AM: Abstract Number: 401

Performance of EULAR/ACR Classification Criteria for Idiopathic Inflammatory Myopathies in a Real-life Cohort of Adult Patients

9:00AM-11:00AM: Abstract Number: 400

Performance of the European League Against Rheumatism/American College of Rheumatology Idiopathic Inflammatory Myopathies Classification Criteria in a Myositis Cohort from Argentina

9:00AM-11:00AM: Abstract Number: 390

Preliminary Response to Janus Kinase (JAK) Inhibition with Baricitinib in Refractory Juvenile Dermatomyositis

9:00AM-11:00AM: Abstract Number: 410

Prevalence of Malignancy in Myositis Patients with Anti-aminoacyl-tRNA Synthetase Antibodies: A Single Center Retrospective Study and Literature Review

9:00AM-11:00AM: Abstract Number: 399

Seasonal and Temporal Analyses of Disease Onset and Diagnosis in Myositis Autoantibody Phenotypes in Juvenile Dermatomyositis (JDM)

9:00AM-11:00AM: Abstract Number: 398

Seasonal Variation in Idiopathic Inflammatory Myopathies Incidence and Presentation: A Retrospective Study in Beijing and Hong Kong

9:00AM-11:00AM: Abstract Number: 394

Sexual Health in 39 Female Patients with Idiopathic Inflammatory Myopathies

9:00AM-11:00AM: Abstract Number: 403

Single-specificity Anti-SMN Autoantibodies Are Associated with a Novel Scleromyositis Overlap Syndrome

9:00AM-11:00AM: Abstract Number: 393

Surfactant Protein D as a Useful Predictor for Mortality in Myositis-associated Interstitial Lung Disease: A Dimorphic Model Based on anti-MDA5 Antibody

9:00AM-11:00AM: Abstract Number: 391

The Beneficial Effects of Rituximab Treatment in Myositis May Be Due to the Binding of a Non B-Cell Protein, SMPDL3B, in Skeletal Muscle

9:00AM-11:00AM: Abstract Number: 388

Treating Statin-induced Anti-HMGCR Myopathy with Normal Muscle Strength: A New Window of Opportunity

9:00AM-11:00AM: Abstract Number: 407

Utility of Anti-SSA/SSB Assay and Anti-Ro 52 Antibody Assay in Routine Clinical Practice for Risk Assessment of Patients with Idiopathic Inflammatory Myositis

9:00AM-11:00AM: Abstract Number: 395

Younger Age at Presentation Is a Risk Factor for Failure to Achieve Remission in Adult Dermatomyositis

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].